DUBLIN – Shares in Santhera Pharmaceuticals Holding AG dropped as much as 33 percent Wednesday on news that it expected its appeal against a negative opinion on the European approval of its Duchenne muscular dystrophy (DMD) drug Raxone (idebenone) to be unsuccessful.